Cirrhosis and Rapid Virological Response to Peginterferon Plus Ribavirin Determine Treatment Outcome in HCV-1 IL28B rs12979860 CC Patients

Table 2

Epidemiological and clinical characteristics stratified by treatment outcome.

	SVR (𝑛=75)	Non-SVR (𝑛=34)	𝑃 value*	OR for non-SVR (95% CI)
Male sex, 𝑛 (%)	41 (55%)	19 (56%)	1	1.05 (0.46–2.37)
Age, years (median)	56	60	0.19	1.02 (0.99–1.07)
BMI > 25, 𝑛 (%)	24 (32%)	15 (44%)	0.29	1.66 (0.73–3.86)
HCV-1a, 𝑛 (%)	13 (18%)	2 (6%)	0.13	0.29 (0.06–1.40)
High viral load, 𝑛 (%)°	44 (59%)	25 (85%)	0.2	1.95 (0.80–4.76)
Cirrhosis, 𝑛 (%)	16 (21%)	14 (41%)	0.03	2.58 (1.07–6.21)
PegIFN alfa-2a, 𝑛 (%)	38 (51%)	12 (41%)	0.15	0.53 (0.23–1.22)

∗Mann-Whitney 𝑈 test for continuous variables, Fisher’s exact test for categorical variables.
°Baseline serum HCV RNA > 0.6 × 10⁶ IU/mL.